NO2280721T3 - - Google Patents
Info
- Publication number
- NO2280721T3 NO2280721T3 NO09753556A NO09753556A NO2280721T3 NO 2280721 T3 NO2280721 T3 NO 2280721T3 NO 09753556 A NO09753556 A NO 09753556A NO 09753556 A NO09753556 A NO 09753556A NO 2280721 T3 NO2280721 T3 NO 2280721T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800565 | 2008-04-17 | ||
| PCT/DK2009/000095 WO2009143843A1 (en) | 2008-04-17 | 2009-04-17 | Indoleamine 2, 3-dioxygenase based immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2280721T3 true NO2280721T3 (https=) | 2018-04-14 |
Family
ID=40873320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO09753556A NO2280721T3 (https=) | 2008-04-17 | 2009-04-17 |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US9433666B2 (https=) |
| EP (3) | EP3320912B1 (https=) |
| JP (2) | JP2011520783A (https=) |
| CN (2) | CN102088994B (https=) |
| AU (1) | AU2009253539B2 (https=) |
| CA (1) | CA2721150C (https=) |
| CY (2) | CY1120352T1 (https=) |
| DK (2) | DK3320912T3 (https=) |
| ES (2) | ES2870596T3 (https=) |
| HR (2) | HRP20180282T1 (https=) |
| HU (2) | HUE037973T2 (https=) |
| IL (1) | IL208781A (https=) |
| LT (2) | LT2280721T (https=) |
| NO (1) | NO2280721T3 (https=) |
| NZ (1) | NZ588757A (https=) |
| PL (2) | PL3320912T3 (https=) |
| PT (2) | PT2280721T (https=) |
| SI (2) | SI3320912T1 (https=) |
| WO (1) | WO2009143843A1 (https=) |
| ZA (1) | ZA201008056B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3320912B1 (en) | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
| EP2425830A1 (en) * | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| JP6605591B2 (ja) * | 2014-05-29 | 2019-11-13 | スプリング バイオサイエンス コーポレーション | 抗インドールアミン２，３−ジオキシゲナーゼ１抗体及びその診断的使用 |
| SI3193917T1 (sl) * | 2014-09-17 | 2022-02-28 | Io Biotech Aps | Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce |
| CN106148276A (zh) * | 2015-04-16 | 2016-11-23 | 中国科学院上海生命科学研究院 | 间充质干细胞在制备治疗神经退行性疾病的药物中的应用 |
| IL255722B2 (en) | 2015-06-29 | 2024-05-01 | Ose Immunotherapeutics | A method for inducing an early memory response with an anticancer vaccine of short peptides |
| US11298413B2 (en) | 2015-09-16 | 2022-04-12 | Io Biotech Aps | Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof |
| HRP20240052T1 (hr) * | 2016-03-04 | 2024-03-29 | Io Biotech Aps | Kombinirana terapija protiv raka |
| EP3468585A2 (en) | 2016-06-10 | 2019-04-17 | IO Biotech APS | Calr and jak2 vaccine compositions |
| AU2017340387A1 (en) * | 2016-10-04 | 2019-05-02 | University Of Florida Research Foundation, Inc. | Targeted effector proteins and uses thereof |
| CN110249056A (zh) * | 2016-10-14 | 2019-09-17 | 苏黎世大学 | 用于前列腺癌诊断及预后的吲哚胺-2,3-双加氧酶检测 |
| RU2769474C2 (ru) * | 2017-01-20 | 2022-04-01 | Атара Байотерапьютикс, Инк. | Способы лечения рассеянного склероза с использованием аутологичных т-клеток |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| SI3573647T1 (sl) | 2017-01-27 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka |
| WO2018138257A1 (en) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| US11407797B2 (en) | 2017-10-11 | 2022-08-09 | University Of Florida Research Foundation, Incorporated | Modified gal-1 proteins and uses thereof |
| NZ765655A (en) | 2017-11-27 | 2026-01-30 | Ose Immunotherapeutics | Improved treatment of cancer |
| US12577282B2 (en) | 2019-02-28 | 2026-03-17 | University Of Florida Research Foundation, Incorporated | Galectin-1/ galectin-3 chimeras and multivalent proteins |
| CN109758467B (zh) * | 2019-03-08 | 2020-12-25 | 中国农业科学院兰州兽医研究所 | 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用 |
| AU2020371562A1 (en) * | 2019-10-23 | 2022-06-09 | The Council Of The Queensland Institute Of Medical Research | Adoptive immunotherapy |
| WO2022006424A2 (en) | 2020-07-02 | 2022-01-06 | The Regents Of The University Of Californa | Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways |
| CN112881269A (zh) * | 2021-02-23 | 2021-06-01 | 浙江正熙生物技术股份有限公司 | 一种流式荧光检测试剂的质量检测方法 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN114657158B (zh) * | 2022-05-25 | 2022-10-21 | 深圳吉诺因生物科技有限公司 | Ido1相关疫苗及其应用 |
| US20240238384A1 (en) * | 2023-01-17 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists |
| EP4669344A2 (en) * | 2023-02-21 | 2025-12-31 | Salvitus, Inc. | Recombinant phages, probiotic vaccines and therapeutic agents, combined compositions and methods of use |
| WO2025093541A1 (en) | 2023-10-31 | 2025-05-08 | Ose Immunotherapeutics | Combination of interleukin 7 and tumour associated antigen vaccine |
| WO2025189043A2 (en) * | 2024-03-07 | 2025-09-12 | Salvitus, Inc. | Oral vaccine compositions and related methods |
| WO2025242193A1 (zh) * | 2024-05-24 | 2025-11-27 | 重庆医科大学 | 博来霉素作为免疫增强剂的用途 |
| WO2026008025A1 (en) * | 2024-07-03 | 2026-01-08 | Everest Medicines (China) Co., Ltd. | Ido1 cancer vaccines and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| AU6180096A (en) * | 1995-06-20 | 1997-01-22 | Merck & Co., Inc. | Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| CN1221349A (zh) | 1996-06-12 | 1999-06-30 | 郭亚军 | 细胞疫苗、免疫治疗以及它们的制备方法 |
| CN1223688A (zh) * | 1996-06-27 | 1999-07-21 | 纳幕尔杜邦公司 | 对羟基苯丙酮酸双加氧酶的植物基因 |
| DE19730066A1 (de) * | 1997-07-14 | 1999-01-21 | Basf Ag | DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen |
| US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
| AU4697600A (en) | 1999-05-03 | 2000-11-17 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
| JP2005503760A (ja) | 2001-01-24 | 2005-02-10 | プロテイン デザイン ラブス， インコーポレイテッド | 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法 |
| AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| US20030148316A1 (en) | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
| WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| US20060292618A1 (en) | 2002-04-12 | 2006-12-28 | Mellor Andrew L | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| CA2483451C (en) | 2002-04-12 | 2014-07-29 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2004053075A2 (en) | 2002-12-05 | 2004-06-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to breast specific genes and proteins |
| RU2005122033A (ru) | 2002-12-13 | 2006-01-27 | Митра Медикал Текнолоджи Аб (Se) | Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом |
| DE10261223A1 (de) | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| US7714139B2 (en) | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| US20050186289A1 (en) * | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| WO2005036127A2 (en) | 2003-10-02 | 2005-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying target cell cytolytic lymphocytes in a sample |
| WO2006005185A1 (en) * | 2004-07-13 | 2006-01-19 | The University Of British Columbia | Indoleamine 2,3-dioxygenase (ido) inhibitors |
| US20060110371A1 (en) | 2004-11-23 | 2006-05-25 | Institut Pasteur | Control of indoleamine 2,3 deoxygenase expression and activity |
| ES2523172T3 (es) | 2005-02-04 | 2014-11-21 | Survac Aps | Vacuna de péptido de survivina |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US7468186B2 (en) | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
| GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| KR101536239B1 (ko) * | 2005-09-23 | 2015-07-13 | 셀레릭스, 에스.엘. | 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도 |
| WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| WO2007115068A2 (en) | 2006-03-30 | 2007-10-11 | Indiana University Research And Technology Corporation | Genetic variants in the indoleamine 2,3-dioxygenase gene |
| WO2008143668A2 (en) * | 2006-05-18 | 2008-11-27 | Lankenau Institute For Medical Research | Indoleamine-2, 3-dioxygenase-2 |
| US8507434B2 (en) * | 2007-01-03 | 2013-08-13 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| EP3320912B1 (en) | 2008-04-17 | 2021-03-31 | IO BIOTECH ApS | Indoleamine 2, 3-dioxygenase based immunotherapy |
-
2009
- 2009-04-17 EP EP17194619.7A patent/EP3320912B1/en active Active
- 2009-04-17 HU HUE09753556A patent/HUE037973T2/hu unknown
- 2009-04-17 EP EP21157371.2A patent/EP3915570A1/en active Pending
- 2009-04-17 ES ES17194619T patent/ES2870596T3/es active Active
- 2009-04-17 SI SI200932129T patent/SI3320912T1/sl unknown
- 2009-04-17 SI SI200931791T patent/SI2280721T1/en unknown
- 2009-04-17 HU HUE17194619A patent/HUE055338T2/hu unknown
- 2009-04-17 JP JP2011504314A patent/JP2011520783A/ja active Pending
- 2009-04-17 LT LTEP09753556.1T patent/LT2280721T/lt unknown
- 2009-04-17 CN CN200980122844.0A patent/CN102088994B/zh active Active
- 2009-04-17 NZ NZ588757A patent/NZ588757A/en unknown
- 2009-04-17 LT LTEP17194619.7T patent/LT3320912T/lt unknown
- 2009-04-17 AU AU2009253539A patent/AU2009253539B2/en active Active
- 2009-04-17 US US12/988,124 patent/US9433666B2/en active Active
- 2009-04-17 EP EP09753556.1A patent/EP2280721B1/en active Active
- 2009-04-17 PL PL17194619T patent/PL3320912T3/pl unknown
- 2009-04-17 DK DK17194619.7T patent/DK3320912T3/da active
- 2009-04-17 PL PL09753556T patent/PL2280721T3/pl unknown
- 2009-04-17 HR HRP20180282TT patent/HRP20180282T1/hr unknown
- 2009-04-17 CN CN201410247727.XA patent/CN104056261B/zh active Active
- 2009-04-17 ES ES09753556.1T patent/ES2657963T3/es active Active
- 2009-04-17 PT PT97535561T patent/PT2280721T/pt unknown
- 2009-04-17 DK DK09753556.1T patent/DK2280721T3/da active
- 2009-04-17 PT PT171946197T patent/PT3320912T/pt unknown
- 2009-04-17 NO NO09753556A patent/NO2280721T3/no unknown
- 2009-04-17 CA CA2721150A patent/CA2721150C/en active Active
- 2009-04-17 WO PCT/DK2009/000095 patent/WO2009143843A1/en not_active Ceased
-
2010
- 2010-10-17 IL IL208781A patent/IL208781A/en active IP Right Grant
- 2010-11-10 ZA ZA2010/08056A patent/ZA201008056B/en unknown
-
2015
- 2015-03-17 JP JP2015052888A patent/JP6016966B2/ja active Active
-
2016
- 2016-08-08 US US15/231,075 patent/US10258678B2/en active Active
-
2018
- 2018-02-12 CY CY20181100171T patent/CY1120352T1/el unknown
-
2019
- 2019-01-29 US US16/261,114 patent/US11324813B2/en active Active
-
2021
- 2021-05-13 HR HRP20210766TT patent/HRP20210766T1/hr unknown
- 2021-06-28 CY CY20211100572T patent/CY1124279T1/el unknown
-
2022
- 2022-03-17 US US17/697,732 patent/US20220202922A1/en not_active Abandoned
- 2022-04-15 US US17/721,577 patent/US11648302B2/en active Active
-
2023
- 2023-04-10 US US18/298,263 patent/US12233103B2/en active Active
-
2025
- 2025-01-17 US US19/028,024 patent/US20250319159A1/en active Pending